Vyleesi Cannabis Interaction Profile: What You Need to Know Before Combining Bremelanotide and Cannabis

What Is Bremelanotide and How Does It Work?

Bremelanotide is a cyclic heptapeptide melanocortin receptor agonist approved by the FDA in June 2019 under the brand name Vyleesi. It is indicated for hypoactive sexual desire disorder (HSDD) in premenopausal women whose low desire is acquired and generalized, not caused by a medical condition, relationship problem, or medication effect. [1]

Mechanism at the Melanocortin Receptors

The drug activates MC1R, MC3R, and MC4R in the central nervous system, particularly in the hypothalamus, to modulate sexual motivation pathways. [2] MC4R activation also affects cardiovascular tone and emesis pathways in the brainstem, which explains why nausea is the most common adverse event, reported in 40% of participants in the phase-3 RECONNECT trials. [3]

Pharmacokinetic Profile

Bremelanotide reaches peak plasma concentration (Cmax approximately 2.3 ng/mL) roughly 1 hour after the 1.75 mg subcutaneous dose. [1] Its elimination half-life is approximately 2.7 hours. Metabolism is primarily via peptide hydrolysis; no cytochrome P450 (CYP) enzymes are significantly involved, which limits classic CYP-mediated drug-drug interactions but does not eliminate pharmacodynamic overlap with other agents. [4]

How Cannabis Affects the Body: Relevant Pharmacology

Cannabis delivers dozens of bioactive compounds, but delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) are the two with the most documented physiological effects. [5] Understanding their individual profiles is necessary before assessing overlap with bremelanotide.

THC: Biphasic Blood Pressure Effects and Antiemetic Action

THC acts on CB1 and CB2 receptors throughout the central nervous system and peripheral tissues. [6] At low doses, THC often raises heart rate and transiently increases blood pressure; at higher doses, orthostatic hypotension becomes a documented risk. [7] THC is also a recognized antiemetic, which is why synthetic THC analogs (dronabinol, nabilone) carry FDA approval for chemotherapy-induced nausea. [8] Paradoxically, heavy, chronic cannabis use is associated with cannabinoid hyperemesis syndrome (CHS), a condition of cyclical, severe vomiting that could be indistinguishable from bremelanotide-induced nausea in a clinical setting. [9]

CBD: CYP Inhibition and Sedation

CBD inhibits CYP3A4 and CYP2C9 in a dose-dependent manner. [10] Although bremelanotide does not rely on CYP3A4 for clearance, patients who use CBD alongside other HSDD-adjacent medications (e.g., buspirone, bupropion) may see altered drug levels. CBD also has sedating properties at higher doses, and sedation may reduce the arousal benefit that bremelanotide aims to produce. [11]

Duration of Cannabis Effects Relevant to Dosing

Smoked or vaped cannabis produces peak THC effects within 10 to 30 minutes, with functional impairment lasting 2 to 4 hours in most occasional users. [12] Edibles delay peak onset to 1 to 3 hours and extend impairment to 6 hours or longer. [12] Because bremelanotide is dosed approximately 45 minutes before sexual activity and remains pharmacologically active for roughly 12 hours, the windows overlap substantially for both smoked and oral cannabis routes.

The Core Interaction: Nausea and Emesis Risk

This is where the clinical concern is most concrete. Nausea occurs in roughly 40% of Vyleesi users and is the leading reason for discontinuation in the RECONNECT phase-3 program. [3]

RECONNECT Trial Nausea Data

In the two key RECONNECT trials (combined N=1,247 premenopausal women with HSDD), 40.0% of bremelanotide-treated patients reported nausea versus 1.4% in the placebo arm. Vomiting occurred in 4.6% on active drug versus 0.3% placebo. [3] Nausea onset was typically within 1 hour of injection and resolved within 12 hours in most patients. The FDA label now includes a boxed section on nausea management recommending an antiemetic (ondansetron 8 mg oral) as needed. [1]

Cannabis and Nausea: A Double-Edged Mechanism

Acute, moderate-dose THC often suppresses nausea via CB1 agonism in the dorsal vagal complex. [13] This might seem protective when used alongside bremelanotide, but the interaction is not that straightforward. Heavy or chronic cannabis users have blunted CB1 receptor sensitivity, meaning the antiemetic benefit is reduced or absent. [14] Chronic users are also at risk of CHS, where the very act of cannabis use triggers vomiting rather than suppressing it. [9] A patient experiencing bremelanotide-induced nausea who also has subclinical CHS could face severe, prolonged emesis with no clear clinical anchor for cause or management.

Clinical Bottom Line on Nausea

Occasional, low-dose cannabis use on the day of a Vyleesi injection does not guarantee worsened nausea for every patient. However, clinicians cannot predict individual CB1 receptor sensitivity, use history, or CHS susceptibility during a standard telehealth intake. Erring toward avoidance is the defensible position until controlled data exist.

Blood Pressure: Additive Hypotension Risk

The FDA label for bremelanotide reports a mean transient decrease in systolic blood pressure of approximately 6 mmHg and diastolic blood pressure of approximately 4 mmHg, peaking around 4 hours post-dose. [1] This effect does not require CYP enzymes and is a direct pharmacodynamic consequence of MC4R activation.

Cannabis-Induced Hypotension

High-dose THC can independently produce orthostatic hypotension through peripheral vasodilation and autonomic modulation. [7] A 2020 analysis published in the European Journal of Preventive Cardiology (Parekh et al., N=1,212) found that cannabis users had a significantly higher rate of orthostatic hypotension compared with non-users (odds ratio 1.60, 95% CI 1.11 to 2.31). [15]

Combined Risk Scenario

A patient who self-administers Vyleesi 45 minutes before sexual activity, then uses cannabis edibles (which have a 1 to 3 hour onset), may experience peak bremelanotide hypotensive effects coinciding with peak cannabis-induced vasodilation. Standing quickly or engaging in physical activity during intercourse under this dual exposure could produce symptomatic hypotension: dizziness, lightheadedness, or syncope. The FDA label already warns against combining bremelanotide with alcohol precisely because of additive hypotension risk. [1] Cannabis shares a physiologically similar concern.

Can I Drink on Vyleesi? Alcohol Versus Cannabis Risk Comparison

The FDA label explicitly states: "Advise patients not to drink alcohol within a few hours of using VYLEESI." [1] This is a labeled, documented warning backed by pharmacokinetic and pharmacodynamic reasoning related to hypotension. Cannabis carries no equivalent labeled warning because no dedicated interaction study has been conducted. That absence of a label warning should not be interpreted as evidence of safety.

The table below compares the two most common co-exposures patients inquire about.

| Factor | Alcohol | Cannabis (THC-dominant) | |---|---|---| | FDA label warning | Yes, explicit | No dedicated study | | Hypotension risk | Additive (vasodilation) | Additive at high doses | | Nausea interaction | May worsen | Dose-dependent; CHS risk in heavy users | | CYP interaction with bremelanotide | Minimal (bremelanotide not CYP-cleared) | CBD inhibits CYP3A4/2C9 but not primary concern | | Recommended window to avoid | A few hours per label | HealthRX advises 4 hours minimum before dosing | | Evidence quality | Clinical pharmacology data | Mechanistic inference only |

Pharmacokinetics: Does Cannabis Change Bremelanotide Blood Levels?

Bremelanotide is cleared primarily via peptide hydrolysis, not through CYP3A4 or CYP2D6 pathways. [4] This means THC is unlikely to raise or lower bremelanotide plasma concentrations through classical enzyme inhibition.

CBD and Off-Target CYP Effects

CBD is a well-characterized inhibitor of CYP3A4 (Ki approximately 3 to 8 microM in human liver microsomes) and CYP2C9. [10] For bremelanotide itself, this is largely irrelevant. Patients who combine high-dose CBD products with other medications prescribed alongside Vyleesi (such as buspirone for comorbid anxiety) should notify their prescribing clinician, because buspirone is a CYP3A4 substrate and CBD may raise its exposure. [16]

Plasma Protein Binding Considerations

Bremelanotide is approximately 21% plasma protein-bound. [1] THC is highly protein-bound (approximately 97%). [17] Competitive displacement at albumin or alpha-1-acid glycoprotein is theoretically possible at very high THC concentrations but has not been documented in clinical data and is unlikely to be clinically meaningful at typical cannabis doses.

Cannabinoid Hyperemesis Syndrome: An Underappreciated Comorbidity

CHS affects a subset of long-term, high-frequency cannabis users. The syndrome involves cyclic, intractable nausea and vomiting relieved only by hot showers or baths and by cessation of cannabis. [9] CHS prevalence among emergency department visits for cyclical vomiting ranges from 2.7% to 32.9% depending on the population studied. [18]

Why CHS Matters for Vyleesi Prescribers

A patient with undiagnosed CHS who begins bremelanotide may present with severe nausea after the first dose. Both CHS and bremelanotide-induced nausea are plausible explanations. Prescribers cannot reliably differentiate them without a thorough cannabis use history. The American College of Gastroenterology recommends screening for cannabis use and CHS in any patient with unexplained cyclic vomiting. [19] Taking a cannabis use history before initiating bremelanotide is therefore not optional.

Sexual Desire, Cannabis, and Competing Mechanisms

Both cannabis and bremelanotide have been studied in the context of sexual function, but in different directions and with mixed findings.

Cannabis and Libido: Mixed Evidence

A cross-sectional analysis published in the Journal of Sexual Medicine (Sun and Eisenberg, 2017, N=50,000 respondents) found that cannabis users reported more frequent sexual intercourse than non-users across all demographic groups. [20] However, cross-sectional design prevents causal inference, and heavy daily cannabis use has been associated with reduced testosterone in male users. [21] For women with HSDD who use cannabis, the net effect on desire is unpredictable.

Bremelanotide's Central Mechanism and Cannabis-Induced Sedation

Bremelanotide works centrally to increase sexual motivation through MC4R. Sedating effects of cannabis, particularly indica-dominant strains and high-dose edibles, may blunt the arousal response that bremelanotide is intended to amplify. A patient who feels cognitively foggy from cannabis may not perceive the modest but statistically significant improvements in desire that bremelanotide provides. In the RECONNECT trials, bremelanotide produced a statistically significant improvement in satisfying sexual events compared with placebo (treatment difference 0.5 events per month, P<0.001). [3] Sedation from concurrent cannabis use could mask or attenuate this benefit.

Who Is Most at Risk from This Combination?

Not every patient who uses cannabis once while on Vyleesi will experience an adverse event. Risk is not uniform.

Higher-Risk Patient Profiles

Patients with a history of orthostatic hypotension, cardiovascular disease, or autonomic dysfunction face the greatest concern for hemodynamic instability under dual exposure. [1] Patients who are daily or near-daily cannabis users are at elevated CHS risk and have attenuated CB1-mediated antiemetic protection. [14] Patients using high-dose CBD supplements alongside other CYP3A4-metabolized medications may see altered drug levels for those co-medications. [10]

Lower-Risk Patient Profiles

Occasional cannabis users with no prior nausea or cardiovascular reactions to cannabis who intend to use a low-potency, smoked product represent a lower, but not zero, theoretical risk. They still warrant counseling on orthostatic hypotension and the importance of remaining seated or lying down for the first few hours after the bremelanotide injection.

HealthRX Clinical Recommendations

The following recommendations apply to patients prescribed bremelanotide who also use cannabis.

Before the Dose

Disclose cannabis use type, frequency, and route of administration to your prescribing clinician. This allows risk stratification and appropriate counseling. If you use cannabis daily or have ever experienced cyclical vomiting episodes relieved by hot showers, discuss CHS screening before starting bremelanotide. [19]

Day-of-Dose Guidance

Avoid cannabis for at least 4 hours before the planned Vyleesi injection. Given bremelanotide's Tmax of approximately 1 hour and its pharmacodynamic activity window of roughly 4 to 6 hours post-dose, avoid cannabis for at least 4 hours after the injection as well. [1] This 8-hour total window provides a conservative buffer against peak overlap of both nausea and blood pressure effects.

Monitoring After Injection

Remain seated or supine for at least 30 minutes after the injection regardless of cannabis status. Monitor for dizziness on standing. If nausea occurs, ondansetron 8 mg oral is the recommended rescue antiemetic per the FDA label. [1] Do not use cannabis as a self-directed antiemetic after a Vyleesi dose, as this reintroduces the interaction risk at the worst possible time.

When to Contact Your Provider

Contact your HealthRX provider if nausea persists beyond 12 hours after a Vyleesi dose, if vomiting is severe or repeated, or if you experience syncope or sustained dizziness. These symptoms warrant clinical evaluation to exclude CHS, cardiovascular causes, and medication adverse events.